John Winslow
Overview
Explore the profile of John Winslow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
582
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Winslow J, Norland R, Storb N, Cannella S, King D
Foot Ankle Spec
. 2016 Feb;
9(6):550-554.
PMID: 26856982
Levels Of Evidence: Therapeutic, Level IV: Case study.
12.
Pollock N, Wang L, Wallweber G, Gooding W, Huang W, Chenna A, et al.
Clin Cancer Res
. 2015 Jul;
21(20):4597-606.
PMID: 26138066
Purpose: In other cancer types, HPV infection has been reported to coincide with overexpression of HER2 (ERBB2) and HER3 (ERBB3); however, the association between HER2 or HER3 expression and dimer...
13.
Duchnowska R, Sperinde J, Chenna A, Huang W, Weidler J, Winslow J, et al.
Neuro Oncol
. 2015 Feb;
17(9):1241-9.
PMID: 25681308
Background: Patients with advanced breast cancer positive for human epidermal growth factor receptor 2 (HER2) are at high risk for brain metastasis (BM). The prevalence and significance of expression of...
14.
Growdon W, Groeneweg J, Byron V, DiGloria C, Borger D, Tambouret R, et al.
Gynecol Oncol
. 2015 Jan;
137(1):160-6.
PMID: 25602714
Background: Subsets of high grade endometrial cancer (EnCa) over-express HER2 (ERBB2), yet clinical trials have failed to demonstrate any anti-tumor activity utilizing trastuzumab, an approved platform for HER2 positive breast...
15.
Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, et al.
Clin Cancer Res
. 2014 Dec;
21(3):569-76.
PMID: 25467182
Purpose: Expression of p95HER2 has been associated with resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Conversely, high levels of HER2 have been linked with increased clinical benefit...
16.
Winslow J
Int J Ther Massage Bodywork
. 2014 Sep;
7(3):25-31.
PMID: 25184012
Study Design: Prospective case series. Background: These case reports present results of the treatment of lateral knee pain in four female amateur triathletes. The athletes were referred to the author's...
17.
Duchnowska R, Sperinde J, Chenna A, Haddad M, Paquet A, Lie Y, et al.
Clin Cancer Res
. 2014 Mar;
20(10):2805-13.
PMID: 24668646
Purpose: P95HER2 (p95) is a truncated form of the HER2, which lacks the trastuzumab-binding site and contains a hyperactive kinase domain. Previously, an optimal clinical cutoff of p95 expression for...
18.
Lipton A, Goodman L, Leitzel K, Cook J, Sperinde J, Haddad M, et al.
Breast Cancer Res Treat
. 2013 Aug;
141(1):43-53.
PMID: 23959396
Trastuzumab is effective in the treatment of HER2/neu over-expressing breast cancer, but not all patients benefit from it. In vitro data suggest a role for HER3 in the initiation of...
19.
DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L, Winslow J
Breast Cancer Res
. 2011 Apr;
13(2):R44.
PMID: 21496232
Introduction: Ligand-bound and phosphorylated ErbB/HER heterodimers are potent signaling forms of this receptor family, and quantitative measurements of these active receptors may be predictive of patient response to targeted therapies....
20.
Ghosh R, Narasanna A, Wang S, Liu S, Chakrabarty A, Balko J, et al.
Cancer Res
. 2011 Feb;
71(5):1871-82.
PMID: 21324925
In breast cancer cells with HER2 gene amplification, HER2 receptors exist on the cell surface as monomers, homodimers, and heterodimers with EGFR/HER3. The therapeutic antibody trastuzumab, an approved therapy for...